Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors

Haemophilia

Volumn 19, Issue 3, 2013, Pages

  Valentino, L A ^a   Allen, G ^b   Gill, J C ^c   Hurlet, A ^d   Konkle, B A ^e   Leissinger, C A ^f   Luchtman Jones, L ^g   Powell, J ^h   Reding, M ⁱ   Stine, K ^j  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f TULANE UNIVERSITY MEDICAL CENTER   (United States)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

more..

Author keywords

Adjuvant therapy; Bypassing therapy; Haemophilia A; Inhibitors; Refractory bleeding

Indexed keywords

AMINOCAPROIC ACID; ANTIBIOTIC AGENT; CYANOACRYLATE; CYCLOPHOSPHAMIDE; DIURETIC AGENT; FENTANYL; FIBRIN GLUE; HYDROMORPHONE; METHADONE; MORPHINE; PREDNISONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; EVIDENCE BASED PRACTICE; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPERTENSION; INTRON; LUNG EDEMA; MALE; PAIN; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE; SURGICAL TECHNIQUE; TREATMENT PLANNING; WEIGHT GAIN;

ADULT; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD COAGULATION FACTOR INHIBITORS; CHILD, PRESCHOOL; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RECOMBINANT PROTEINS;

EID: 84876814770     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12095     Document Type: Article

References (128)

1. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 48-52. discussion -3.
2. Berntorp E, Collins P, D'Oiron R et al. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 2011; 17: e202-10.
3. Onwuzurike N, Warrier I, Lusher JM. Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B. Haemophilia 1996; 2: 137-40.
4. Escuriola Ettingshausen C, Halimeh S, Kurnik K et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-20.
5. Franchini M, Rossetti G, Tagliaferri A et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11: 504-9.
6. Ghosh K, Shetty S, Jijina F, Mohanty D. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia 2004; 10: 58-62.
7. Schexneider KI. Fibrin sealants in surgical or traumatic hemorrhage. Curr Opin Hematol 2004; 11: 323-6.
8. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
9. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
10. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
11. Berntorp E. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. Haemophilia 2007; 13(Suppl. 5): 69-72.
12. Graham CA, Parke TR. Critical care in the emergency department: shock and circulatory support. Emerg Med J 2005; 22: 17-21.
13. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
14. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63: 47-52.
15. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-40.
16. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257-9.
17. Jindra P, Koza V, Boudova L et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation. Bone Marrow Transplant 2003; 31: 951-2.
18. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38: 1120-7.
19. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16(Suppl. 1): S27-31.
20. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77(Suppl. 1): 25-7.
21. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
22. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
23. Clinical Trials.gov. Study of first time immunotolerance induction in severe hemophilia A patients with inhibitor at high risk of failure: comparison with FVIII concentrates with or without von Willebrand factor - RES.I.S.T. Naive (RESIST NAIVE). Available at http://www.clinicaltrials.gov/ct2/show/NCT01051544?term=resisT&rank=6. Accessed April 23, 2012.
24. Clinical Trials.gov. Rescue immunotolerance study in induction of immune tolerance (ITI)-experienced patients (RES.I.S.T. Experienced) (RESIST EXP). Availableat http://www.clinicaltrials.gov/ct2/show/NCT01051076?term=resist&recr=Open&cond=hemophilia+inhibitor&rank=2. Accessed April 23, 2012.
25. Observational Immune Tolerance Induction Research Program (ObsITI). Available at http://www.obsiti.com/index.php?id=about-obsiti. Accessed August 13, 2012.
26. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629-48.
27. National Institute of Diabetes and Digestive and Kidney Diseases. Vascular access for hemodialysis. NIH Publication No. 05-4554. January 2005. Available at http://www.kidney.niddk.nih.gov/kudiseases/pubs/pdf/vascularaccess.pdf. Accessed September 20, 2011.
28. Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966; 275: 1089-92.
29. Kherlakian GM, Roedersheimer LR, Arbaugh JJ, Newmark KJ, King LR. Comparison of autogenous fistula versus expanded polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg 1986; 152: 238-43.
30. Lumsden AB, MacDonald MJ, Allen RC, Dodson TF. Hemodialysis access in the pediatric patient population. Am J Surg 1994; 168: 197-201.
31. McCarthy WJ, Valentino LA, Bonilla AS et al. Arteriovenous fistula for long-term venous access for boys with hemophilia. J Vasc Surg 2007; 45: 986-90. discussion 90-1.
32. Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica 2009; 94: 687-92.
33. Miao CH. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 2010; 3: 469-83.
34. Miao CH, Ye P, Thompson AR, Rawlings DJ, Ochs HD. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood 2006; 108: 19-27.
35. Qian J, Burkly LC, Smith EP et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
36. Hausl C, Ahmad RU, Schwarz HP et al. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood 2004; 104: 115-22.
37. Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588-92.
38. Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000; 6: 66-70.
39. Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003; 9: 50-6.
40. Titapiwatanakun R, Moir C, Pruthi RK, Stavlo PL, Schmidt KA, Rodriguez V. Central venous access devices for paediatric patients with haemophilia: a single-institution experience. Haemophilia 2009; 15: 168-74.
41. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
42. Van Dijk K, Van Der Bom JG, Bax KN, Van Der Zee DC, Van Den Berg MH. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica 2004; 89: 189-94.
43. Damiano ML, Hutter JJ Jr. Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia 2000; 6: 526-32.
44. Warrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment center experience. Haemophilia 1997; 3: 194-8.
45. Morado M, Jimenez-Yuste V, Villar A et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001; 7: 551-6.
46. Onland W, Shin CE, Fustar S, Rushing T, Wong WY. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med 2006; 160: 1049-53.
47. Forestier R, Andre-Vert J, Guillez P et al. Non-drug treatment (excluding surgery) in rheumatoid arthritis: clinical practice guidelines. Joint Bone Spine 2009; 76: 691-8.
48. Vliet Vlieland TP, Pattison D. Non-drug therapies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23: 103-16.
49. Varni JW. Behavioral medicine in hemophilia arthritic pain management: two case studies. Arch Phys Med Rehabil 1981; 62: 183-7.
50. Tsoukas C, Eyster ME, Shingo S et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood 2006; 107: 1785-90.
51. York J. Haemophilia patients with inhibitors: a rheumatologist's point of view. In: Rodriguez-Merchan EC, Lee CA eds. Inhibitors in Patients with Haemophilia. Oxford, England: Blackwell Science, Ltd., 2002: 146-8.
52. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'Bonn protocol'. Vox Sang 1996; 70(Suppl. 1): 30-5.
53. FEIBA NF [package insert]. Westlake Village, CA: Baxter Healthcare Corporation, 2011.
54. Valentino LA, Kawji M, Grygotis M. Venous access in the management of hemophilia. Blood Rev 2011; 25: 11-5.
55. Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-9.
56. Van den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia-a review. Haemophilia 1998; 4: 418-20.
57. Aledort LM, DiMichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
58. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
59. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
60. Gringeri A, Musso R, Bernasconi S. Immunotolerance induction (ITI) with high purity FVIII/VWF concentrates in inhibitor patients with a high risk of a poor response to ITI: a prospective surveillance. J Thromb Haemost 2005; 3(Suppl. 1): A207.
61. Silva M, Luck JV Jr, Siegel ME. 32P chromic phosphate radiosynovectomy for chronic haemophilic synovitis. Haemophilia 2001; 7: 40-9.
62. Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC. Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost 2005; 3: 1541-2.
63. Infante-Rivard C, Rivard GE, Derome F, et al. A retrospective cohort study of cancer incidence among patients treated with radiosynoviorthesis. Haemophilia 2012; 18: 805-9.
64. Wakeford R. The cancer epidemiology of radiation. Oncogene 2004; 23: 6404-28.
65. Kleinerman RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 2006; 36(Suppl. 2): 121-5.
66. Rodriguez-Merchan EC. Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis. Clin Orthop Relat Res 1997; 343: 6-11.
67. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
68. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
69. Rattray B, Nugent DJ, Young G. Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia 2005; 11: 240-4.
70. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12: 514-7.
71. Dargaud Y, Bordet JC, Lienhart A, Negrier C. Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII. Semin Hematol 2008; 45: S72-3.
72. Dargaud Y, Lienhart A, Meunier S et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11: 552-8.
73. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
74. Viuff D, Andersen S, Sorensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. Thromb Res 2010; 126: 144-9.
75. Hayashi T, Tanaka I, Shima M et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10: 397-400.
76. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
77. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
78. Wegert W, Harder S, Bassus S, Kirchmaier CM. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa. Platelets 2005; 16: 45-50.
79. Campbell RA, Fischer TH, Wolberg AS. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation. Br J Haematol 2007; 138: 82-93.
80. Pereboom IT, De Boer MT, Haagsma EB, Hendriks HG, Lisman T, Porte RJ. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. Anesth Analg 2009; 108: 1083-91.
81. Centers for Disease Control and Prevention. Fatal bacterial infections associated with platelet transfusions-Unites States, 2004. MMWR 2005; 54: 168-70.
82. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168: 2377-81.
83. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
84. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
85. Eckhardt CL, Menke LA, Van Ommen CH et al. Intensive peri-operative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
86. Von Auer C, Oldenburg J, Von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
87. Verbruggen B, Novakova I, Wessels H, Boezeman J, Van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
88. Blanco AN, Peirano AA, Grosso SH, Gennari LC, Bianco RP, Lazzari MA. An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients. Haematologica 2000; 85: 1045-50.
89. Towfighi F, Gharagozlou S, Sharifian RA et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84-90.
90. Franchini M, Girelli D, Olivieri O et al. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A. Haemophilia 2006; 12: 448-51.
91. Franchini M, Salvagno GL, Lippi G. Inhibitors in mild/moderate haemophilia A: an update. Thromb Haemost 2006; 96: 113-8.
92. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
93. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
94. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Hemophilia 2007; 13(Suppl. 1): 1-22.
95. Dunkley S, Kershaw G, Young G et al. Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol. Haemophilia 2006; 12: 663-7.
96. Spina M, Jaeger U, Sparano JA et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105: 1891-7.
97. Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258-66.
98. Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
99. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
100. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004; 41: 140-4.
101. Young G, Ebbesen LS, Viuff D et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
102. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
103. Kenet G, Stenmo CB, Blemings A et al. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 2010; 103: 351-9.
104. Rodriguez-Merchan EC. Orthopaedic surgery of haemophilia in the 21st century: an overview. Haemophilia 2002; 8: 360-8.
105. Barg A, Elsner A, Hefti D, Hintermann B. Haemophilic arthropathy of the ankle treated by total ankle replacement: a case series. Haemophilia 2010; 16: 647-55.
106. Min ZH, Zhang HM. [Study on short-term effects of ankle replacement for the treatment of hemophilic arthritis]. Zhongguo Gu Shang 2009; 22: 428-31.
107. Berdel P, Schott D, Pagenstert G et al. [Upper ankle joint prostheses in haemophilia patients]. Hamostaseologie 2009; 29(Suppl. 1): S65-8.
108. Radossi P, Bisson R, Munari F et al. Total ankle replacement for end-stage arthropathy in patients with haemophilia. Haemophilia 2008; 14: 658-60.
109. Limbird TJ, Dennis SC. Synovectomy and continuous passive motion (CPM) in hemophiliac patients. Arthroscopy 1987; 3: 74-9.
110. Chen PQ, Shen MC, Tsai YC, Liu TK. Surgical management of musculoskeletal involvement in hemophilic patients. Taiwan Yi Xue Hui Za Zhi 1989; 88: 911-8.
111. Glassner PJ, Slover JD, Bosco JA 3rd, Zuckerman JD. Blood, bugs, and motion - what do we really know in regard to total joint arthroplasty? Bull NYU Hosp Jt Dis 2011; 69: 73-80.
112. Postel JM, Thoumie P, Missaoui B et al. Continuous passive motion compared with intermittent mobilization after total knee arthroplasty. Elaboration of French clinical practice guidelines. Ann Readapt Med Phys 2007; 50: 244-57.
113. Fazalare JA, Griesser MJ, Siston RA, Flanigan DC. The use of continuous passive motion following knee cartilage defect surgery: a systematic review. Orthopedics 2010; 33: 878.
114. Lachiewicz PF. The role of continuous passive motion after total knee arthroplasty. Clin Orthop Relat Res 2000; 380: 144-50.
115. Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004; 10(Suppl. 2): 30-40.
116. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
117. Teitel JM, Carcao M, Lillicrap D et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227-39.
118. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
119. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
120. Gringeri A, Fischer K, Karafoulidou A, Klamroth R, Lopez-Fernandez MF, Mancuso E. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17: 630-5.
121. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-a European perspective. Crit Care 2006; 10: R120.
122. Gringeri A, Mantovani LG, Scalone L, Mannucci PM, for the COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
123. Valentino L, Tarantino M, Pipe S, Ye X, Xiong Y, Luo M. Healthcare resource utilization among hemophilia A patients with inhibitor status in the US. Poster presented at the World Federation of Hemophilia Congress; July 10-14, 2010; Buenos Aires, Argentina.
124. Llinas A, Silva M, Pasta G et al. Controversial subjects in musculoskeletal care of haemophilia: cross fire. Haemophilia 2010; 16(Suppl. 5): 132-5.
125. Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia 2011; 17: 11-6.
126. DiMichele DM, Lasak ME, Miller CH. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion. Am J Hematol 1996; 51: 99-103.
127. Antunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003; 9: 573-7.
128. Luchtman-Jones L, Valentino LA, Manno C, and Recombinant Therapy Workshop Participants. Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. Haemophilia 2006; 12: 82-6.